PMID- 23280245
OWN - NLM
STAT- MEDLINE
DCOM- 20130906
LR  - 20211203
IS  - 1873-2534 (Electronic)
IS  - 0165-2427 (Linking)
VI  - 151
IP  - 3-4
DP  - 2013 Feb 15
TI  - Species-specific properties and translational aspects of canine dendritic cells.
PG  - 181-92
LID - S0165-2427(12)00427-8 [pii]
LID - 10.1016/j.vetimm.2012.12.003 [doi]
AB  - Dogs are affected by spontaneously occurring neoplastic and inflammatory diseases 
      which often share many similarities with pathological conditions in humans and 
      are thus appreciated as important translational animal models. Dendritic cells 
      (DCs) represent the most potent antigen presenting cell population. Besides their 
      physiological function in the initiation of primary T cell responses and B cell 
      immunity, a deregulation of DC function is involved in immune-mediated tissue 
      damage, immunosuppression and transplantation complication in human and 
      veterinary medicine. DCs represent a promising new target for cancer 
      immunotherapy in dogs. However, the therapeutic use of canine DCs is restricted 
      because of a lack of standardized isolation techniques and limited information 
      about dog-specific properties of this cell type. This article reviews current 
      protocols for the isolation and in vitro generation of canine monocyte- and bone 
      marrow-derived DCs. DCs of dogs are characterized by unique morphological 
      features, such as the presence of cytoplasmic projections and periodic 
      microstructures. Canine DCs can be discriminated from other hematopoietic cells 
      also based on phenotypic properties and their high T cell stimulatory capability 
      in mixed leukocyte reactions. Furthermore, the classification of canine 
      DC-derived neoplasms and the role of DCs in the pathogeneses of selected 
      infectious, allergic and autoimmune diseases, which share similarities with human 
      disorders, are discussed. Future research is needed to expand the existing 
      knowledge about DC function in canine diseases as a prerequisite for the 
      development of future therapies interfering with the immune response.
CI  - Copyright (c) 2012 Elsevier B.V. All rights reserved.
FAU - Qeska, V
AU  - Qeska V
AD  - Department of Pathology, University of Veterinary Medicine, Hannover, Bunteweg 
      17, 30559 Hannover, Germany.
FAU - Baumgartner, W
AU  - Baumgartner W
FAU - Beineke, A
AU  - Beineke A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121213
PL  - Netherlands
TA  - Vet Immunol Immunopathol
JT  - Veterinary immunology and immunopathology
JID - 8002006
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/immunology/therapeutic use
MH  - Cell Lineage/immunology
MH  - Cytokines/metabolism
MH  - Dendritic Cells/cytology/*immunology
MH  - Dog Diseases/immunology
MH  - Dogs/*immunology
MH  - Humans
MH  - Immune System Diseases/immunology/veterinary
MH  - Immunotherapy/veterinary
MH  - Infections/immunology/veterinary
MH  - Lymphocyte Activation
MH  - Models, Animal
MH  - Neoplasms/immunology/therapy/veterinary
MH  - Phagocytosis
MH  - Species Specificity
MH  - T-Lymphocytes/immunology
MH  - Translational Research, Biomedical
EDAT- 2013/01/03 06:00
MHDA- 2013/09/07 06:00
CRDT- 2013/01/03 06:00
PHST- 2012/08/14 00:00 [received]
PHST- 2012/11/20 00:00 [revised]
PHST- 2012/12/06 00:00 [accepted]
PHST- 2013/01/03 06:00 [entrez]
PHST- 2013/01/03 06:00 [pubmed]
PHST- 2013/09/07 06:00 [medline]
AID - S0165-2427(12)00427-8 [pii]
AID - 10.1016/j.vetimm.2012.12.003 [doi]
PST - ppublish
SO  - Vet Immunol Immunopathol. 2013 Feb 15;151(3-4):181-92. doi: 
      10.1016/j.vetimm.2012.12.003. Epub 2012 Dec 13.